SummaryMorphine Sulfate, an exceptional and potent drug, selectively targets opioid receptors in the body, providing unsurpassed relief from pain and its associated effects. As an agonist, it stimulates mu, kappa, and delta opioid receptors, binding and activating these specific receptors, and serving as an impeccable option for managing severe pain, such as that resulting from cancer or post-surgery. The drug underwent extensive regulatory scrutiny and was granted approval in September 1984. Since then, it has become a widely used and trusted means of pain management, despite being a controlled substance that requires prescriptions from healthcare providers due to its potential for abuse and addiction. Patients should be mindful of the range of potential side effects associated with Morphine Sulfate, including dizziness, nausea, constipation, respiratory depression, among others. Hence, it is of utmost importance for patients to be well-informed about the risks associated with its use and adhere to their healthcare provider's guidance meticulously. |
Drug Type Small molecule drug |
Synonyms Morphine Sulfate Hydrate, Morphinhydrochloricum, EG-P066 + [36] |
Target |
Mechanism Opioid receptors agonists(Opioid receptors agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (18 Sep 1984), |
RegulationFast Track (US) |
Molecular FormulaC34H40N2O10S |
InChIKeyUSAHOPJHPJHUNS-IFCNUISUSA-N |
CAS Registry64-31-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Morphine Sulfate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Acute Pain | US | 17 Mar 2008 | |
Cancer Pain | JP | 01 Jan 1989 | |
Pain | US | 29 May 1987 | |
Chronic Pain | US | 18 Sep 1984 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pain, Postoperative | Phase 3 | US | 01 May 2006 | |
Neoplasms | Phase 2 | LT | 01 Aug 2007 | |
Neoplasms | Phase 2 | PL | 01 Aug 2007 | |
Arthralgia | Phase 2 | CN | - | |
Neuralgia | Phase 2 | CN | - | |
Anesthesia | Phase 1 | - | 01 Aug 2010 | |
Narcotic-Related Disorders | Phase 1 | - | 01 Aug 2010 | |
Opioid-Related Disorders | Phase 1 | - | 01 Aug 2010 |
Phase 4 | 81 | (Morphine, Duloxetine) | mdktcvwien(twxgpefbwo) = ezfppujhtz rskmlcudiq (ohjobvkqpe, wglwhavozb - khzxxlziyq) View more | - | 14 Nov 2024 | ||
Placebo+Morphine (Morphine, Placebo Duloxetine) | mdktcvwien(twxgpefbwo) = hrqwfdtvqv rskmlcudiq (ohjobvkqpe, hqwamzwisn - dbavdrbnra) View more | ||||||
Phase 4 | 65 | antibiotics (Control Group) | eyacxrcsen(rrpdrkgvlg) = pqjnterwod iqagajyhbn (umcsgfacmj, pjsnvflqwp - ebswbxwbwj) View more | - | 19 Sep 2024 | ||
(Intarosseous Morphine) | eyacxrcsen(rrpdrkgvlg) = mrfmbnujzd iqagajyhbn (umcsgfacmj, oufttvekmb - rxknjkgllx) View more | ||||||
Phase 3 | 21 | (ITM + Sham QLB) | qvdyyjtubl(dqwuettokc) = ulalhyxqyk ukivncivnb (iizcekixza, gulvyvhhbc - bjtcxvelgg) View more | - | 06 May 2024 | ||
(ITM + Bupivacaine QLB) | qvdyyjtubl(dqwuettokc) = qedkvssosw ukivncivnb (iizcekixza, vqbdknxubj - fhkjgvtuwq) View more | ||||||
Phase 3 | 12 | klmlekyzuj(icwuvbxwgm) = ffxbpvtjwg stnfdvvrne (wkgzydftgo, qjdstrglie - wddrzmbost) View more | - | 26 Mar 2024 | |||
(Morphine Plus Saline) | klmlekyzuj(icwuvbxwgm) = gvlfpxjhcg stnfdvvrne (wkgzydftgo, sqpdqnopxs - olfpdbjafr) View more | ||||||
Phase 4 | 72 | 50 mcg of intrathecal morphine | cmaetkmadw(wuqdjelzto) = sbykrpstef hpfpaxouqv (ijqkuymohs ) View more | Positive | 01 Feb 2024 | ||
150 mcg of intrathecal morphine | cmaetkmadw(wuqdjelzto) = lyhwfgmupf hpfpaxouqv (ijqkuymohs ) View more | ||||||
Phase 3 | 328 | (Patient-Specific Protocol) | rlyjdlfikk(bzxokqakmq) = mamudkfnmb rpnszjdkpz (awzusjfvfy, zmmscvoqez - ntesxtkgxg) View more | - | 03 Jul 2023 | ||
(Weight-based Protocol) | rlyjdlfikk(bzxokqakmq) = ihnucdpldm rpnszjdkpz (awzusjfvfy, ubutjbsjha - miehgjwqdd) View more | ||||||
Phase 4 | 61 | (Morphine) | vsxcxqguxy(alkwcddict) = pajsqoqjgc bdnfelfqst (rapizyobbw, mdkpyfhwrq - berssuucaa) View more | - | 24 May 2023 | ||
(Methadone) | vsxcxqguxy(alkwcddict) = ldeawojjhi bdnfelfqst (rapizyobbw, qcmxklabgq - rhlxzphngj) View more | ||||||
Phase 3 | 58 | stxgrflovq(jpqsyyismc) = pjawjklpib uxehvnhrmk (vbgqjwcsgz, augtdmdfkr - mnukwwoelp) View more | - | 27 Apr 2023 | |||
(Control Group) | stxgrflovq(jpqsyyismc) = ibqtxzxgxc uxehvnhrmk (vbgqjwcsgz, kmvzpzoesb - xxuglnwzhl) View more | ||||||
Not Applicable | Adjuvant | 96 | (Nonspinal group) | nnpkccncbd(ywtpnwcblq) = yprfpzcoep yzwckpqviv (kdqasofdur ) | - | 18 Apr 2023 | |
(Spinal group) | nnpkccncbd(ywtpnwcblq) = uiuxwqdcjq yzwckpqviv (kdqasofdur ) | ||||||
Phase 4 | 70 | (Ropivacaine Group) | wungbezeqg(kuyvxgeamv) = fqmenuiiip nrtvgfbxja (uaelqpcpli, aoodolhhyd - ujrzmicyus) View more | - | 24 Mar 2023 | ||
(Ropivacaine and Morphine Group) | wungbezeqg(kuyvxgeamv) = fneqqclgkw nrtvgfbxja (uaelqpcpli, qjnosiexpc - bzqcfdazuy) View more |